Alliance Health Group, UK

alliancehealthgroup.co.uk

Alliance Health Group has a unique approach to healthcare, we put consultants at the heart of the patient pathway. Through our partnerships with major insurers such as VitalityHealth we have worked collaboratively to achieve impressive NPS scores of 57. Alliance Health Group provide healthcare trusts for companies such as Rolls-Royce plc, Mitie and Anglian Water. Our consultants streamline the patient pathway and manage the process from day one, meaning a faster, more clinically focused and a more efficient journey for the patient, saving significant amounts by streamlining pathways to cut out unnecessary financial waste.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

news image

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More

MedTech

BIOWISH TECHNOLOGIES AND SABIC AGRI-NUTRIENTS COMPANY ANNOUNCE BIO-ENHANCED MINERAL FERTILIZER COLLABORATION

BiOWiSH Technologies, Inc. | July 22, 2022

news image

BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents and nine different crop types. BiOWiSH® Crop Liquid is a blend of proprietary microbial cultures that can be coated onto dry fertilizer or mixed with liquid fertilizers to create an enhanced efficiency fertilizer specifically designed to op...

Read More

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

news image

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More

Industrial Impact

LEGEND BIOTECH ACHIEVES MILESTONE PAYMENTS IN BCMA CAR-T COLLABORATION WITH JANSSEN

Legend Biotech Corporation | February 14, 2022

news image

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. Legend Biotech entered into the agreement with Janssen to d...

Read More
news image

Research

CELYAD ONCOLOGY ANNOUNCES CLOSING OF $32.5 MILLION PRIVATE PLACEMENT WITH FORTRESS INVESTMENT GROUP AFFILIATE

Celyad Oncology SA | December 09, 2021

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced the closing of its previously announced private placement with an affiliate of Fortress Investment Group. The Company issued 6,500,000 ordinary shares at a price of USD 5.00 for gross proceeds of USD 32.5 million. The Company intends to use net proceeds from the private placement to fund research and developme...

Read More
news image

MedTech

BIOWISH TECHNOLOGIES AND SABIC AGRI-NUTRIENTS COMPANY ANNOUNCE BIO-ENHANCED MINERAL FERTILIZER COLLABORATION

BiOWiSH Technologies, Inc. | July 22, 2022

BiOWiSH Technologies, Inc. and SABIC Agri-Nutrients Company announced the successful completion of a year-long technical evaluation of BiOWiSH® Crop Liquid technology coated on SABIC’s urea in nine countries across five continents and nine different crop types. BiOWiSH® Crop Liquid is a blend of proprietary microbial cultures that can be coated onto dry fertilizer or mixed with liquid fertilizers to create an enhanced efficiency fertilizer specifically designed to op...

Read More
news image

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More
news image

Industrial Impact

LEGEND BIOTECH ACHIEVES MILESTONE PAYMENTS IN BCMA CAR-T COLLABORATION WITH JANSSEN

Legend Biotech Corporation | February 14, 2022

Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, has achieved two milestones under its collaboration agreement with Janssen Biotech, Inc. for ciltacabtagene autoleucel (cilta-cel), resulting in aggregate payments to Legend Biotech of $50 million. Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. Legend Biotech entered into the agreement with Janssen to d...

Read More